Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
Adult
Alemtuzumab
/ administration & dosage
Behavioral Symptoms
/ drug therapy
Brain Diseases
/ drug therapy
Brain Stem
/ pathology
Cognitive Dysfunction
/ drug therapy
Fingolimod Hydrochloride
/ administration & dosage
Humans
Immunologic Factors
/ administration & dosage
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting
/ complications
Mutism
/ drug therapy
Recurrence
White Matter
/ pathology
Young Adult
Alemtuzumab
Brainstem
Multiple sclerosis
Posterior fossa syndrome
Relapse
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
30
04
2019
revised:
07
11
2019
accepted:
10
11
2019
pubmed:
30
11
2019
medline:
20
1
2021
entrez:
29
11
2019
Statut:
ppublish
Résumé
Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions. The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing-remitting MS, significantly responsive to Alemtuzumab treatment. 24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment. Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localization.
Sections du résumé
BACKGROUND
BACKGROUND
Posterior fossa syndrome (PFS) is a rare manifestation of ponto-mesencephalic lesions frequently reported in post-surgical pediatric tumors, rarely described as a consequence of vascular, infective or inflammatory lesions.
OBJECTIVE
OBJECTIVE
The aim of this article is to report the clinical and neuroradiological characteristics of a patient with an acute PFS presentation as a relapse in relapsing-remitting MS, significantly responsive to Alemtuzumab treatment.
CASE REPORT
METHODS
24-year-old patient affected by multiple sclerosis developed motor-cognitive and behavioral syndrome related to an extensive ponto-mesencephalic lesion under Fingolimod treatment.
CONCLUSION
CONCLUSIONS
Our case highlights the significant and rapid effect of Alemtuzumab therapy on both cognitive and motor symptoms occurring during a MS relapse with atypical neuroradiological localization.
Identifiants
pubmed: 31778927
pii: S2211-0348(19)30839-9
doi: 10.1016/j.msard.2019.101518
pii:
doi:
Substances chimiques
Immunologic Factors
0
Alemtuzumab
3A189DH42V
Fingolimod Hydrochloride
G926EC510T
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
101518Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.